|
Jun 21
|
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
|
|
Jun 12
|
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
|
|
Jun 7
|
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 15
|
Jaguar Health Inc (JAGX) Q1 2024 Earnings Call Transcript Highlights: Strategic Expansions and ...
|
|
May 14
|
Jaguar Health Reports First Quarter 2024 Financial Results
|
|
May 13
|
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
|
|
May 9
|
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
|
|
May 8
|
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
|
|
May 7
|
Want $10,000? Invest $1,000 in These 3 Penny Stocks Now
|
|
May 6
|
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
|
|
Apr 29
|
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
|
|
Apr 22
|
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
|
|
Apr 18
|
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
|
|
Apr 16
|
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
|
|
Apr 9
|
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
|
|
Apr 8
|
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
|
|
Apr 3
|
Jaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)
|
|
Apr 2
|
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcript
|
|
Apr 2
|
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
|
|
Apr 2
|
Q4 2023 Jaguar Health Inc Earnings Call
|